What is HC Wainwright’s Estimate for ETON FY2024 Earnings?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Investment analysts at HC Wainwright reduced their FY2024 EPS estimates for shares of Eton Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 26th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.17) for the year, down from their previous estimate of ($0.15). HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q4 2024 earnings at ($0.04) EPS and FY2028 earnings at $1.58 EPS.

Separately, Craig Hallum lifted their target price on Eton Pharmaceuticals from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, October 28th.

Eton Pharmaceuticals Stock Up 2.3 %

Shares of ETON stock opened at $12.74 on Thursday. The stock has a market cap of $329.15 million, a price-to-earnings ratio of -56.05 and a beta of 1.25. Eton Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $12.77. The business’s fifty day moving average is $8.23 and its 200 day moving average is $5.36.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Parkman Healthcare Partners LLC lifted its position in Eton Pharmaceuticals by 2.8% during the third quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock valued at $1,561,000 after purchasing an additional 7,029 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Eton Pharmaceuticals in the third quarter worth about $54,000. Westside Investment Management Inc. grew its stake in Eton Pharmaceuticals by 2.0% during the 2nd quarter. Westside Investment Management Inc. now owns 585,400 shares of the company’s stock worth $1,926,000 after buying an additional 11,440 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Eton Pharmaceuticals during the third quarter worth $90,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Eton Pharmaceuticals by 86.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after purchasing an additional 30,167 shares during the last quarter. Institutional investors own 27.86% of the company’s stock.

Insider Transactions at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc. acquired 57,500 shares of the stock in a transaction dated Tuesday, September 10th. The shares were acquired at an average cost of $4.65 per share, for a total transaction of $267,375.00. Following the completion of the transaction, the insider now directly owns 2,660,000 shares of the company’s stock, valued at approximately $12,369,000. The trade was a 2.21 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have acquired 85,600 shares of company stock worth $462,674 in the last 90 days. 14.89% of the stock is currently owned by insiders.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.